Aberdeen Group plc Acquires New Stake in GSK PLC Sponsored ADR $GSK

GSK logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Aberdeen Group acquired 583,300 GSK shares in the third quarter, valued at approximately $28.1 million; institutional investors collectively own 15.74% of the stock.
  • Analyst sentiment is broadly neutral: GSK has a consensus “Hold” rating and an average price target of $56.30, based on three Buy, 13 Hold, and three Sell ratings.
  • GSK raised its quarterly dividend slightly to $0.4518 per share, equivalent to an annualized dividend of about $1.81 and a 3.6% yield.
  • Five stocks to consider instead of GSK.

Aberdeen Group plc acquired a new stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 583,300 shares of the pharmaceutical company's stock, valued at approximately $28,098,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Mondrian Investment Partners LTD increased its holdings in GSK by 1.1% in the 3rd quarter. Mondrian Investment Partners LTD now owns 4,965,946 shares of the pharmaceutical company's stock worth $239,210,000 after acquiring an additional 55,116 shares during the last quarter. Equity Investment Corp lifted its holdings in GSK by 8.9% during the third quarter. Equity Investment Corp now owns 3,560,824 shares of the pharmaceutical company's stock valued at $171,525,000 after purchasing an additional 291,059 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in GSK by 2.1% during the third quarter. Russell Investments Group Ltd. now owns 1,060,376 shares of the pharmaceutical company's stock valued at $51,078,000 after purchasing an additional 22,275 shares during the last quarter. NewEdge Advisors LLC boosted its position in GSK by 842.9% during the second quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company's stock worth $49,986,000 after purchasing an additional 852,437 shares during the period. Finally, Foster Victor Wealth Advisors LLC boosted its position in GSK by 5.8% during the third quarter. Foster Victor Wealth Advisors LLC now owns 438,220 shares of the pharmaceutical company's stock worth $21,674,000 after purchasing an additional 23,934 shares during the period. 15.74% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Morgan Stanley reissued an "underweight" rating on shares of GSK in a research report on Tuesday, August 25th. HSBC reaffirmed a "hold" rating on shares of GSK in a report on Thursday, September 10th. Wolfe Research assumed coverage on GSK in a research report on Friday, October 9th. They issued an "outperform" rating and a $70.00 price target for the company. Deutsche Bank reiterated a "neutral" rating on shares of GSK in a research note on Tuesday, September 29th. Finally, Wall Street Zen lowered GSK from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Three investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $56.30.

Read Our Latest Stock Analysis on GSK

GSK Stock Performance

NYSE:GSK opened at $50.41 on Tuesday. The business has a 50 day moving average of $49.31 and a 200 day moving average of $52.40. The company has a market capitalization of $101.96 billion, a price-to-earnings ratio of 10.66, a PEG ratio of 2.28 and a beta of 0.29. GSK PLC Sponsored ADR has a 1-year low of $45.81 and a 1-year high of $61.69. The company has a debt-to-equity ratio of 1.18, a current ratio of 0.86 and a quick ratio of 0.56.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 7th. Shareholders of record on Friday, November 13th will be given a dividend of $0.4518 per share. The ex-dividend date is Friday, November 13th. This is an increase from GSK's previous quarterly dividend of $0.4515. This represents a $1.81 dividend on an annualized basis and a yield of 3.6%. GSK's dividend payout ratio (DPR) is 61.46%.

GSK Profile

(Free Report)

GSK plc is a global biopharmaceutical company headquartered in the United Kingdom. It researches, develops and manufactures medicines and vaccines, with a focus on areas including infectious diseases, HIV, respiratory and immune conditions, and cancer. Its products include vaccines such as Shingrix, which helps prevent shingles, and Arexvy, for respiratory syncytial virus (RSV). GSK also makes specialty medicines, including treatments for HIV and respiratory diseases, and continues to develop new medicines and vaccines through its research programs.

Featured Stories

Institutional Ownership by Quarter for GSK (NYSE:GSK)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GSK Right Now?

Before you consider GSK, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.

While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines